Treatment of metastatic colorectal cancer: focus on panitumumab
作者： Eliza Hawkes , Rebecca Tay , Rachel Wong
DOI: 10.2147/CMAR.S71821
关键词: Colorectal cancer 、 Biomarker (medicine) 、 Oncology 、 Panitumumab 、 Cetuximab 、 Epidermal growth factor receptor 、 Fluorouracil 、 Internal medicine 、 KRAS 、 Chemotherapy 、 Bioinformatics 、 Medicine
摘要: Targeted agents are an important therapeutic option in the treatment of metastatic colorectal cancer (mCRC). Panitumumab is a recombinant, fully humanized, immunoglobulin G2 monoclonal antibody that targets epidermal growth factor receptor (EGFR) with efficacy mCRC as monotherapy and combination chemotherapy. Kirsten rat sarcoma (KRAS) mutation status has emerged biomarker to predict response anti-EGFR therapy. Optimal timing for panitumumab use algorithm not been established. This review discusses mechanism action, predictive biomarkers, role mCRC.
iaea.org参考文章(49)
C.H. Köhne, R. Labianca, T. Price, W. Scheithauer, A. Sobrero, J. Tabernero, D. Aderka, S. Barroso, G. Bodoky, J.Y. Douillard, H. El Ghazaly, J. Gallardo, A. Garin, R. Glynne-Jones, K. Jordan, A. Meshcheryakov, D. Papamichail, P. Pfeiffer, I. Souglakos, S. Turhal, A. Cervantes, H.J. Schmoll, E. Van Cutsem, A. Stein, V. Valentini, B. Glimelius, K. Haustermans, B. Nordlinger, C.J. van de Velde, J. Balmana, J. Regula, I.D. Nagtegaal, R.G. Beets-Tan, D. Arnold, F. Ciardiello, P. Hoff, D. Kerr, ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making Annals of Oncology. ,vol. 23, pp. 2479- 2516 ,(2012) , 10.1093/ANNONC/MDS236
Ana Custodio, Jaime Feliu, Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations. Critical Reviews in Oncology Hematology. ,vol. 85, pp. 45- 81 ,(2013) , 10.1016/J.CRITREVONC.2012.05.001
J. Randolph Hecht, Edith Mitchell, Tarek Chidiac, Carroll Scroggin, Christopher Hagenstad, David Spigel, John Marshall, Allen Cohn, David McCollum, Philip Stella, Robert Deeter, Seta Shahin, Rafael G. Amado, A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 27, pp. 672- 680 ,(2009) , 10.1200/JCO.2008.19.8135
Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Ursula Vehling-Kaiser, Salah-Eddin Al-Batran, Tobias Heintges, Christian Lerchenmüller, Christoph Kahl, Gernot Seipelt, Frank Kullmann, Martina Stauch, Werner Scheithauer, Jörg Hielscher, Michael Scholz, Sebastian Müller, Hartmut Link, Norbert Niederle, Andreas Rost, Heinz-Gert Höffkes, Markus Moehler, Reinhard U Lindig, Dominik P Modest, Lisa Rossius, Thomas Kirchner, Andreas Jung, Sebastian Stintzing, FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial Lancet Oncology. ,vol. 15, pp. 1065- 1075 ,(2014) , 10.1016/S1470-2045(14)70330-4
Alberto Bardelli, Simona Corso, Andrea Bertotti, Sebastijan Hobor, Emanuele Valtorta, Giulia Siravegna, Andrea Sartore-Bianchi, Elisa Scala, Andrea Cassingena, Davide Zecchin, Maria Apicella, Giorgia Migliardi, Francesco Galimi, Calogero Lauricella, Carlo Zanon, Timothy Perera, Silvio Veronese, Giorgio Corti, Alessio Amatu, Marcello Gambacorta, Luis A. Diaz, Mark Sausen, Victor E. Velculescu, Paolo Comoglio, Livio Trusolino, Federica Di Nicolantonio, Silvia Giordano, Salvatore Siena, Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer Cancer Discovery. ,vol. 3, pp. 658- 673 ,(2013) , 10.1158/2159-8290.CD-12-0558
Claus-Henning Köhne, Ralf Hofheinz, Laurent Mineur, Henry Letocha, Richard Greil, Josef Thaler, Eva Fernebro, Erick Gamelin, Lucy DeCosta, Meinolf Karthaus, First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer Journal of Cancer Research and Clinical Oncology. ,vol. 138, pp. 65- 72 ,(2012) , 10.1007/S00432-011-1061-6
Joe J Stephenson, Charles Gregory, Howard Burris, Tim Larson, Udit Verma, Allen Cohn, Jeffrey Crawford, Roger B Cohen, Julie Martin, Peggy Lum, Xinqun Yang, Rafael G Amado, None, An open-label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumors Clinical Colorectal Cancer. ,vol. 8, pp. 29- 37 ,(2009) , 10.3816/CCC.2009.N.005
Luis A. Diaz, Alberto Bardelli, Liquid Biopsies: Genotyping Circulating Tumor DNA Journal of Clinical Oncology. ,vol. 32, pp. 579- 586 ,(2014) , 10.1200/JCO.2012.45.2011
V Martin, L Landi, F Molinari, G Fountzilas, R Geva, A Riva, P Saletti, S De Dosso, A Spitale, S Tejpar, K T Kalogeras, L Mazzucchelli, M Frattini, F Cappuzzo, HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients British Journal of Cancer. ,vol. 108, pp. 668- 675 ,(2013) , 10.1038/BJC.2013.4
Andreia Costa, Sabine Tejpar, Hans Prenen, Eric Van Cutsem, Hypomagnesaemia and targeted anti-epidermal growth factor receptor (EGFR) agents Targeted Oncology. ,vol. 6, pp. 227- 233 ,(2011) , 10.1007/S11523-011-0200-Y